Skip to content

Examination for the effect of combination therapy with alendronate and eldecalcitol in primary osteoporotic patients :A randomized active comparator study -Switch from alfacalcidol to eldecalcitol-

Examination for the effect of combination therapy with alendronate and eldecalcitol in primary osteoporotic patients :A randomized active comparator study -Switch from alfacalcidol to eldecalcitol- - Examination for the effect of combination therapy with alendronate and eldecalcitol for osteoporosis -Switch from alfacalcidol to eldecalcitol-

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000006964
Enrollment
120
Registered
2011-12-27
Start date
2012-01-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Interventions

Alendronate (35mg/week) + alfacalcidol (1.0ug/day) for 48 weeks Alendronate (35mg/week) + eldecalcitol (0.75ug/day) for 48 weeks

Sponsors

Tokyo Women's Medical University Medical Center East
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Primary osteoporotic patients (2) Patients who are treated with alendronate and alfacalcidol for more than 24 weeks and less than five years (3) Patients with informed of consent

Exclusion criteria

Exclusion criteria: (1) Patients who are diagnosed as contraindication of alendronate treatments (2) Patients who are diagnosed as contraindication of eldecalcitol treatments (3) Patients who are treated with glucocorticoid (4) Patients who have serum calcium levels of above 10.5mg/dL (5) Patients who have taken osteoporosis treatments other than alendronate and alfacalcidol (6) Patients who are inappropriate for this study by physician

Design outcomes

Primary

MeasureTime frame
Change of lumbar spine bone mineral density

Secondary

MeasureTime frame
Change of total hip bone mineral density Number of fracture occurred Change of bone metabolic markers Safety

Countries

Japan

Contacts

Public ContactYasuo Inoue

Tokyo Women's Medical University Medical Center East Department of Orthopaedic Surgery

i-yasuo2@apr.so-net.jp03-3810-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026